Jiangsu Hengrui Medicine
600276.SSJiangsu Hengrui Medicine Co., Ltd. is a leading Chinese pharmaceutical company founded in 1970, headquartered in Lianyungang, Jiangsu Province. The company has evolved from producing generic drugs to becoming a major innovator in oncology, with particular strength in developing novel cancer treatments, anesthesia drugs, and medical imaging contrast agents. Hengrui has established itself as one of China's most valuable pharmaceutical companies with significant R&D investments and an expanding global footprint.
600276.SS · Stock Price
Historical price data
AI Company Overview
Jiangsu Hengrui Medicine Co., Ltd. is a leading Chinese pharmaceutical company founded in 1970, headquartered in Lianyungang, Jiangsu Province. The company has evolved from producing generic drugs to becoming a major innovator in oncology, with particular strength in developing novel cancer treatments, anesthesia drugs, and medical imaging contrast agents. Hengrui has established itself as one of China's most valuable pharmaceutical companies with significant R&D investments and an expanding global footprint.
Technology Platform
Integrated pharmaceutical platform specializing in small molecule and biologic drug discovery, with particular expertise in immuno-oncology, antibody-drug conjugates, and precision medicine approaches.
Pipeline
719| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Remimazolam Tosilate | Sedation in the Upper Gastrointestinal Endoscopy | Approved | |
| Henagliflozin 10 mg daily + Metformin 1700 mg daily | Metabolic Dysfunction-associated Steatotic Liver Disease | Approved | |
| Imrecoxib | Knee Osteoarthritis | Approved | |
| Ivarmacitinib | Rheumatoid Arthritis | Approved | |
| Bupivacaine Liposome Injection | Local Analgesia Via Infiltration | Approved |
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Hengrui competes with leading Chinese biotech companies like BeiGene and Innovent Biologics domestically, while facing global competition from established players like Roche, Merck, and Bristol Myers Squibb in oncology. The company differentiates itself through its comprehensive commercial infrastructure in China, cost-effective development model, and growing international capabilities.